Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate in Patients With Persistent Asthma
15 de janeiro de 2015 atualizado por: Novartis Pharmaceuticals
A Multicenter, Randomized, Double-blind, Placebo-controlled, 12-week Treatment, Parallel-group Study to Assess the Efficacy, Safety and Pharmacokinetics of Indacaterol Acetate (75 and 150 µg o.d.) in Patients With Persistent Asthma
To provide the efficacy, safety and pharmacokinetics of indacaterol acetate in patients with persistent asthma to support dose selection of indacaterol in fixed dose combination QMF149.
Visão geral do estudo
Status
Concluído
Condições
Intervenção / Tratamento
Tipo de estudo
Intervencional
Inscrição (Real)
335
Estágio
- Fase 2
Contactos e Locais
Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.
Locais de estudo
-
-
-
Bad Woerishofen, Alemanha, 86825
- Novartis Investigative Site
-
Bonn, Alemanha, 53123
- Novartis Investigative Site
-
Dortmund, Alemanha, 44263
- Novartis Investigative Site
-
Dresden, Alemanha, 01307
- Novartis Investigative Site
-
Frankfurt, Alemanha, 60596
- Novartis Investigative Site
-
Lübeck, Alemanha, 23552
- Novartis Investigative Site
-
Mainz, Alemanha, 55131
- Novartis Investigative Site
-
Muenchen, Alemanha, 81677
- Novartis Investigative Site
-
Wiesbaden, Alemanha, 65187
- Novartis Investigative Site
-
Wiesloch, Alemanha, 69168
- Novartis Investigative Site
-
-
-
-
-
Lovech, Bulgária, 5500
- Novartis Investigative Site
-
Pleven, Bulgária, 5800
- Novartis Investigative Site
-
Plovdiv, Bulgária, 4002
- Novartis Investigative Site
-
Ruse, Bulgária, 7002
- Novartis Investigative Site
-
Sofia, Bulgária, 1431
- Novartis Investigative Site
-
Sofia, Bulgária, 1233
- Novartis Investigative Site
-
Sofia, Bulgária, 1606
- Novartis Investigative Site
-
Sofia, Bulgária, 1612
- Novartis Investigative Site
-
Sofia, Bulgária, 1000
- Novartis Investigative Site
-
Sofia, Bulgária, 1234
- Novartis Investigative Site
-
Sofia, Bulgária, 1463
- Novartis Investigative Site
-
Varna, Bulgária, 9000
- Novartis Investigative Site
-
Varna, Bulgária, 9020
- Novartis Investigative Site
-
Veliko Tarnovo, Bulgária, 5000
- Novartis Investigative Site
-
-
-
-
Ontario
-
Brampton, Ontario, Canadá, L6T 0G1
- Novartis Investigative Site
-
Downsview, Ontario, Canadá, M3N 2Z9
- Novartis Investigative Site
-
Etobicoke, Ontario, Canadá, M9V 4B4
- Novartis Investigative Site
-
Grimsby, Ontario, Canadá, L3M 1P3
- Novartis Investigative Site
-
Hamilton, Ontario, Canadá, L8N 3Z5
- Novartis Investigative Site
-
Newmarket, Ontario, Canadá, L3Y 5G8
- Novartis Investigative Site
-
Toronto, Ontario, Canadá, M5T 3A9
- Novartis Investigative Site
-
Woodstock, Ontario, Canadá, N4S 5P5
- Novartis Investigative Site
-
-
Quebec
-
Montreal, Quebec, Canadá, H4J 1C5
- Novartis Investigative Site
-
Pointe-Claire, Quebec, Canadá, H9R 4S3
- Novartis Investigative Site
-
St-Romuald, Quebec, Canadá, G6W 5M6
- Novartis Investigative Site
-
Ste-Foy, Quebec, Canadá, G1W 4R4
- Novartis Investigative Site
-
-
-
-
-
Dunajska Streda, Eslováquia, 929 01
- Novartis Investigative Site
-
Komarno, Eslováquia, 945 01
- Novartis Investigative Site
-
Kosice, Eslováquia, 040 01
- Novartis Investigative Site
-
Liptovsky Hradok, Eslováquia, 033 01
- Novartis Investigative Site
-
Liptovsky Mikulas, Eslováquia, 031 23
- Novartis Investigative Site
-
Nove Zamky, Eslováquia, 940 01
- Novartis Investigative Site
-
Rimavska Sobota, Eslováquia, 979 01
- Novartis Investigative Site
-
Spisská Nová Ves, Eslováquia, 052 01
- Novartis Investigative Site
-
Topolcany, Eslováquia, 955 01
- Novartis Investigative Site
-
Vysne Hagy, Eslováquia, 5984
- Novartis Investigative Site
-
Zvolen, Eslováquia, 960 01
- Novartis Investigative Site
-
-
Slovak Republic
-
Banska Bystrica, Slovak Republic, Eslováquia, 975 17
- Novartis Investigative Site
-
Bardejov, Slovak Republic, Eslováquia, 085 01
- Novartis Investigative Site
-
-
Slovak republic
-
Levice, Slovak republic, Eslováquia, 934 01
- Novartis Investigative Site
-
-
-
-
-
Rotterdam, Holanda, 3045 PM
- Novartis Investigative Site
-
Sittard-Geleen, Holanda, 6162 BG
- Novartis Investigative Site
-
-
-
-
-
Fukuoka, Japão, 811-1394
- Novartis Investigative Site
-
Gifu, Japão, 502-8558
- Novartis Investigative Site
-
-
Fukuoka
-
Yanagawa, Fukuoka, Japão, 832-0059
- Novartis Investigative Site
-
-
Hokkaido
-
Obihiro, Hokkaido, Japão, 080-0805
- Novartis Investigative Site
-
Sapporo-city, Hokkaido, Japão, 060-0061
- Novartis Investigative Site
-
-
Hyogo
-
Himeji-city, Hyogo, Japão, 672-8064
- Novartis Investigative Site
-
-
Hyogo-Ken
-
Ako-shi, Hyogo-Ken, Japão, 678-0241
- Novartis Investigative Site
-
-
Ibaraki
-
Naka-gun, Ibaraki, Japão, 319-1113
- Novartis Investigative Site
-
-
Kagawa
-
Sakaide, Kagawa, Japão, 762-0031
- Novartis Investigative Site
-
-
Kyoto-Fu
-
Kyoto-shi, Kyoto-Fu, Japão, 615-8256
- Novartis Investigative Site
-
-
Mie
-
Tsu, Mie, Japão, 514-1101
- Novartis Investigative Site
-
-
Oita
-
Beppu, Oita, Japão, 874-0937
- Novartis Investigative Site
-
-
Oita-Ken
-
Oita-shi, Oita-Ken, Japão, 870-0021
- Novartis Investigative Site
-
-
Osaka
-
Kishiwada, Osaka, Japão, 596-8501
- Novartis Investigative Site
-
-
Tokyo
-
Chuo-ku, Tokyo, Japão, 103-0027
- Novartis Investigative Site
-
Cyuo-ku, Tokyo, Japão, 104-8560
- Novartis Investigative Site
-
Itabashi-ku, Tokyo, Japão, 173-8610
- Novartis Investigative Site
-
Kiyose-city, Tokyo, Japão, 204-8585
- Novartis Investigative Site
-
Setagaya-ku, Tokyo, Japão, 158-0097
- Novartis Investigative Site
-
-
Tokyo-To
-
Machida-shi, Tokyo-To, Japão, 194-0023
- Novartis Investigative Site
-
Ota-ku, Tokyo-To, Japão, 144-0035
- Novartis Investigative Site
-
-
Yamagata
-
Yonezawa, Yamagata, Japão, 992-0045
- Novartis Investigative Site
-
-
-
-
-
Bialystok, Polônia, 15-461
- Novartis Investigative Site
-
Bienkowka, Polônia, 34-212
- Novartis Investigative Site
-
Bydgoszcz, Polônia, 85-046
- Novartis Investigative Site
-
Gdansk, Polônia, 80-958
- Novartis Investigative Site
-
Krakow, Polônia, 31-023
- Novartis Investigative Site
-
Lodz, Polônia, 90-302
- Novartis Investigative Site
-
Lodz, Polônia, 90-242
- Novartis Investigative Site
-
Lublin, Polônia, 20-637
- Novartis Investigative Site
-
Lublin, Polônia, 20-044
- Novartis Investigative Site
-
Torun, Polônia, 87-100
- Novartis Investigative Site
-
Wroclaw, Polônia, 50-088
- Novartis Investigative Site
-
Znin, Polônia, 88-400
- Novartis Investigative Site
-
-
-
-
-
Seoul, Republica da Coréia, 120-752
- Novartis Investigative Site
-
Seoul, Republica da Coréia, 158-710
- Novartis Investigative Site
-
Seoul, Republica da Coréia, 152-703
- Novartis Investigative Site
-
Seoul, Republica da Coréia, 100-032
- Novartis Investigative Site
-
-
Chungbuk
-
Cheongju, Chungbuk, Republica da Coréia, 361 711
- Novartis Investigative Site
-
-
Gangwon-Do
-
Wonju, Gangwon-Do, Republica da Coréia, 220-701
- Novartis Investigative Site
-
-
Korea
-
Seoul, Korea, Republica da Coréia, 110 744
- Novartis Investigative Site
-
-
Critérios de participação
Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.
Critérios de elegibilidade
Idades elegíveis para estudo
18 anos e mais velhos (Adulto, Adulto mais velho)
Aceita Voluntários Saudáveis
Não
Gêneros Elegíveis para o Estudo
Tudo
Descrição
Inclusion Criteria:
- Patients with persistent asthma, diagnosed according to GINA 2010 guideline and who additionally meet the following criteria:
- Patients who are receiving ICS treatment in a stable regimen for ≥ 4 weeks
- Patients with a pre-bronchodilator FEV1 value of ≥ 40% and ≤ 80% of predicted normal value
- Patients who demonstrate an increase of >= 12% and 200 mL in FEV1
- ACQ-5 score ≥ 1.5
Exclusion Criteria:
- Patients who are current smokers or have a smoking history of greater than 10 pack years (defined as the number of packs of 20 cigarettes smoked per day multiplied by number of years the patient smoked).
- Patients with chronic lung disease, including COPD, pulmonary tuberculosis, bronchiectasis, sarcoidosis, interstitial lung disease and cystic fibrosis.
- Patients with any chronic conditions affecting the respiratory tract (e.g., chronic sinusitis) which in the opinion of the investigator may interfere with the study evaluation or optimal participation in the study.
Other protocol-defined inclusion/exclusion criteria may apply
Plano de estudo
Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: indacaterol acetate 75 µg
indacaterol acetate 75 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od |
indacaterol acetate 75 µg or indacaterol acetate 150 µg delivered via Concept 1 inhaler
via Twisthaler inhaler
|
|
Experimental: indacaterol acetate 150 µg
indacaterol acetate 150 µg od delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od |
indacaterol acetate 75 µg or indacaterol acetate 150 µg delivered via Concept 1 inhaler
via Twisthaler inhaler
|
|
Comparador de Placebo: placebo
placebo delivered via Concept 1 inhaler Background therapy: mometasone furoate 200 mcg od |
via Twisthaler inhaler
placebo delivered via Concept 1 inhaler
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Trough Forced Expiratory Volume in One Second (FEV1) After 12 Weeks (Day 85)
Prazo: after 12 weeks (Day 85)
|
Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards.
Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose after 12 weeks (Day 85)
|
after 12 weeks (Day 85)
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Asthma Control Questionnaire 5 (ACQ-5) After 12 Weeks (Day 85)
Prazo: aftert 12 weeks (Day 85)
|
The Asthma Control Questionnaire (ACQ-5) is a validated questionnaire consisting of 5 items for the assessment of asthma symptom which are night symptom, morning symptom, limitation for the activities, shortness of breath, and wheeze.
The ACQ-5 score is the mean of the 5 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled).
A negative change in score indicates improvement in symptoms.
MIXED model: Change from baseline in ACQ-5 = treatment + gender + baseline ACQ-5 score + age + level of asthma control + region + center (region) + error.
Center is included as a random effect nested within region.
|
aftert 12 weeks (Day 85)
|
|
Trough Forced Expiratory Volume in One Second (FEV1) After 2 Weeks (Day 15), 4 Weeks (Day 29), and 8 Weeks (Day 57) of Treatment.
Prazo: Day 15, Day 29 and Day 57
|
Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards.
Trough FEV1 was defined as the average of measurements made 23 hours 10 minutes and 23 hours 45 minutes post-dose after 2 weeks (Day 15), 4 weeks (Day 29), and 8 weeks (Day 57) of treatment.
|
Day 15, Day 29 and Day 57
|
|
Forced Vital Capacity (FVC) on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85 at All Time Points
Prazo: Day 1, Day 2, Day 14, Day 15, Day 84, Day 85
|
Forced Vital Capacity (FVC) was measured via spirometry conducted according to internationally accepted standards.
FVC is measured on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85 at all time points
|
Day 1, Day 2, Day 14, Day 15, Day 84, Day 85
|
|
Forced Expiratory Volume in One Second (FEV1)/ Forced Vital Capacity (FVC) on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85
Prazo: Day 1, Day 2, Day 14, Day 15, Day 84, Day 85
|
Forced Expiratory Volume in 1 second (FEV1)/Forced Vital Capacity (FVC) was measured via spirometry conducted according to internationally accepted standards.
|
Day 1, Day 2, Day 14, Day 15, Day 84, Day 85
|
|
Forced Expiratory Flow (FEF 25-75% )on Day 1, Day 2, Day 14, Day 15, Day 84, Day 85
Prazo: Day 1, Day 2, Day 14, Day 15, Day 84, Day 85
|
Forced Expiratory Flow (FEF 25-75%) was measured via spirometry conducted according to internationally accepted standards.
|
Day 1, Day 2, Day 14, Day 15, Day 84, Day 85
|
|
Standardized Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC) at (5 Min - 4 h), (5 Min - 1 h) (1 h - 4 h) Measured on Day 1, 2 Weeks (Day 14)&12 Weeks (Day 84)
Prazo: Day 1, 2 Weeks, 12 Weeks
|
Forced Expiratory Volume in 1 second (FEV1)/Area Under the Curve(AUC) was measured via spirometry conducted according to internationally accepted standards.FEV1 AUC(5 min - 4 h), (5 min - 1 h) and (1 h - 4 h) are measured at Day 1, 2 Weeks (Day 14) and 12 Weeks (Day84) and defined as average of FEV1 at specified timepoints above.
|
Day 1, 2 Weeks, 12 Weeks
|
|
Peak Forced Expiratory Volume in 1 Second (FEV1) at Day 1, 2 Weeks (Day 14), 12 Weeks (Day 84)
Prazo: Day 1, 2 weeks (Day 14), 12 weeks (Day 84)
|
Peak Forced Expiratory Volume in 1 second (FEV1) was measured via spirometry conducted according to internationally accepted standards.
Peak FEV1 is defined as the maximum FEV1 during the first 4 h post morning dosing at Day 1, 2Weeks and 12 Weeks.
|
Day 1, 2 weeks (Day 14), 12 weeks (Day 84)
|
|
Asthma Control Questionnaire 5 (ACQ-5) After 4 Weeks (Day 29) and After 8 Weeks (Day 57) of Treatment
Prazo: after 4 weeks (Day 29) and after 8 weeks (Day 57)
|
The ACQ-5 is a validated questionnaire consisting of 5 items for the assessment of asthma symptom which are night symptom, morning symptom, limitation for the activities, shortness of breath, and wheeze.
Each item is graded on a scale of 0-6 and the questions are equally weighted.
The ACQ-5 score is the mean of the 5 questions and therefore between 0 (totally controlled) and 6 (severely uncontrolled).
|
after 4 weeks (Day 29) and after 8 weeks (Day 57)
|
|
Morning and Evening Peak Expiratory Flow Rate (PEFR) Over 12 Weeks of Treatment. This is LS Mean of the Treatment Period.
Prazo: baseline, 4weeks, 8 weeks and 12 weeks
|
PEFR is measured with portable spirometer by participants every morning and evening at home.
|
baseline, 4weeks, 8 weeks and 12 weeks
|
|
The Usage of Rescue Medication (Short Acting β2-agonist) Over 12 Weeks of Treatment
Prazo: 12 weeks
|
Participants record the number of puffs of rescue medication taken in the previous 12 hours in the morning and nighttime.
|
12 weeks
|
|
Asthma Quality of Life Questionnaire (AQLQ(S)) After 4 Weeks (Day 29) and 12 Weeks (Day 85) of Treatment
Prazo: 4 Weeks, 12 Weeks
|
The AQLQ is a 32-item disease specific questionnaire designed to measure functional impairments in asthma.
Patients are asked to score each item on a 7-point scale based on the experience of last 2 weeks.
The overall AQLQ score is the mean response to all 32 questions.
Therefore, the possible highest score (better) would be 7 and the lowest (worse) would be 1.
Changes in scores of 0.5 to 1.0 are considered clinically meaningful; 1.0 to 1.5 as moderate and > 1.5 as marked clinically important differences for any individual domain or for the overall summary score.
|
4 Weeks, 12 Weeks
|
|
Time to First Asthma Exacerbation (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period
Prazo: 12 weeks
|
Duration of treatment until first asthma exacerbation by severity of exacerbation.
A severe asthma exacerbation is systemic corticosteroids (SCS) use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma.
A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h).
Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.
|
12 weeks
|
|
The Annual Rate of Asthma Exacerbations (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period
Prazo: 12 weeks
|
Annual incidence rate of asthma exacerbation by severity of exacerbation.
The number of asthma exacerbation is used to calculate annual incidence rate.
A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma.
A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h).
Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.
Number of the asthma exacerbation will be analyzed by the negative binomial regression including treatment, history of asthma exacerbation in the 12 months prior to screening and region as factors and FEV1 prior to inhalation and FEV1 30 min post inhalation of salbutamol/albuterol (components of SABA reversibility) as covariates.
The estimates are obtained from the model and so we cannot specify a formula.
|
12 weeks
|
|
Duration of Asthma Exacerbations (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period
Prazo: 12 weeks
|
Duration of asthma exacerbations by severity of exacerbation.
A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma.
A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h).
Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.
|
12 weeks
|
|
The Percentage of Patients With at Least One Asthma Exacerbation (Mild, Moderate, Severe, Moderate or Severe and Any) Over the 12 Week Treatment Period
Prazo: 12 weeks
|
The percentage of patients with at least one asthma exacerbation by severity of exacerbation.
A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma.
A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h).
Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.
|
12 weeks
|
|
Time to Permanent Study Discontinuation Due to Asthma Exacerbation Over the 12 Week Treatment Period
Prazo: 12 weeks
|
Time to permanent study discontinuation due to asthma exacerbation.
A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma.
A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h).
Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.
|
12 weeks
|
|
The Percentage of Patients Who Permanently Discontinued Study Due to Asthma Exacerbation Over the 12 Week Treatment Period
Prazo: 12 weeks
|
The percentage of patients who permanently discontinued study due to asthma exacerbation.
A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma.
A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h).
Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.
|
12 weeks
|
|
Total Amounts (in Doses) of Systemic Corticosteroids Used to Treat Asthma Exacerbations Over the 12 Week Treatment Period
Prazo: 12 weeks
|
Total amounts (in doses) of systemic corticosteroids (SCS) used to treat asthma exacerbations.SCS includes Intramuscular (IM), Intravenous (IV) and Oral.
A severe asthma exacerbation is SCS use ≥3 days and hospitalization or emergency department visit (greater than 24 h) or death due to asthma.
A moderate asthma exacerbation is SCS use ≥3 days either as an outpatient or in emergency department visits (less than or equal to 24 h).
Worsening of asthma not requiring more than 3 days of SCS or hospitalization/emergency room will be considered mild asthma exacerbations.
|
12 weeks
|
|
Plasma Indacaterol Concentrations at Day 1 and Day 14
Prazo: Day 1 and Day 14
|
Maximum plasma concentration after drug administration (Cmax) was measured for indacaterol acetate 75 µg and indacaterol acetate 150 µg for Pharmacokinetic (PK) Subgroup
|
Day 1 and Day 14
|
Colaboradores e Investigadores
É aqui que você encontrará pessoas e organizações envolvidas com este estudo.
Patrocinador
Datas de registro do estudo
Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.
Datas Principais do Estudo
Início do estudo
1 de agosto de 2012
Conclusão Primária (Real)
1 de julho de 2013
Conclusão do estudo (Real)
1 de julho de 2013
Datas de inscrição no estudo
Enviado pela primeira vez
23 de abril de 2012
Enviado pela primeira vez que atendeu aos critérios de CQ
29 de maio de 2012
Primeira postagem (Estimativa)
1 de junho de 2012
Atualizações de registro de estudo
Última Atualização Postada (Estimativa)
27 de janeiro de 2015
Última atualização enviada que atendeu aos critérios de controle de qualidade
15 de janeiro de 2015
Última verificação
1 de janeiro de 2015
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- CQMF149E2203
- 2012-000520-18 (Número EudraCT)
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .